You are here:

Drugs in development

The development of new drugs is a long and difficult process. Fewer than one or two compounds in 10,000 tested actually make it through to being licensed treatments with many being rejected on safety, efficacy or quality grounds.

On average it will take 10-15 years for a new compound to get from the test-tube into the medicine cabinet. It is important to remember that not all the treatments currently being developed or tested will receive a license or be approved for use in the NHS.

Consultant Neurologist Martin Duddy tells us about the newest MS drugs on the horizon:

You can browse the tables below to see which drugs are in the pipeline for relapsing remitting, secondary progressive and primary progressive MS.

Drugs in the pipeline for relapsing remitting MS

Drug in development

Status

ATX-MS-1467 Phase II
Laquinimod Phase III
Ocrelizumab NHS appraisal
Ofatumumab Phase II
Ozanimod Phase III
Ponesimod Phase III

Drugs in the pipeline for secondary progressive MS

Drug in development

Status

Amiloride Phase II
Fluoxetine Phase II
Ibudilast Phase II
Masitinib Phase III
MD1003 (Biotin) Phase III
Opicinumab (Anti-LINGO-1, BIIB033) Phase II
Riluzole Phase II
Simvastatin Phase III
Siponimod Phase III

Drugs in the pipeline for primary progressive MS

Drug in development

Status

Ibudilast Phase II
Idebenone Phase II
Laquinimod Phase II
Masitinib Phase III
MD1003 (Biotin) Phase III
Ocrelizumab NHS appraisal
Opicinumab (Anti-LINGO-1, BIIB033) Phase II

Remyelination and neuroprotection

Drug in development

Status

Bexarotene Phase II

What does the drug development process involve?


Phase I:
The first step in testing a new drug is to determine the safety of single doses in a small number of healthy volunteers.

Phase II
If the treatment proves to be safe, studies begin to determine the effectiveness of the drug in people with the condition to be treated.

Phase III
If a drug shows effectiveness, a larger study is conducted in hundreds of people.

Licensing
Data from all of these three phases is presented to the regulatory authorities.

NHS appraisal: 
Once a new medicine has been licensed, drugs may need to be appraised by NICE for England and Wales and SMC for Scotland.

 

Last updated: January 2018

This page will be reviewed within three years

Print this page

Rate this page:

Fieldset
*Any personal information will not be followed up or be given to third parties.
*Any personal information will not be followed up or be given to third parties.
*Any personal information will not be followed up or be given to third parties.
*Any personal information will not be followed up or be given to third parties.
*Any personal information will not be followed up or be given to third parties.

Please fill in the fields below if you would like to stay in touch with the MS Trust to help with further testing and feedback on the MS Trust website

Do you have a question about MS? Contact our enquiry team